Comments from Website author: This article also
discusses the type of collagen that composes [unnamed
product] (typeII) with significant effect in
reducing rheumatoid arthritis.
Comments from Physicians at this article's end: None
Beth Israel hospital, Boston, MA 02215, USA.
OBJECTIVE: To evaluate the efficacy of oral chicken type II collagen (CCII) in the treatment of juvenile rheumatoid arthritis (JRA). METHODS: Ten patients with active JRA were treated with CCII for 12 weeks. Efficacy parameters, which included swollen and tender joint count and score, grip strength, 50-foot walking time, duration of morning stiffness, and patient and physician global scores of disease severity, were assessed monthly. RESULTS: All patients completed the full course of therapy. Eight patients had reductions in both swollen and tender joint counts after 3 months of CCII. The mean changes from baseline in swollen and tender joint counts for the 8 responders at the end of the study were -61% and -54%, respectively. Mean values for other efficacy parameters also showed improvement from baseline. There were no adverse events that were considered to be treatment related. CONCLUSION: Oral CCII may be a safe and effective therapy for JRA, and its use in this disease warrants further investigation.
MeSH Terms:
Administration, Oral; Adolescence; Arthritis, Juvenile Rheumatoid/therapy*;
Arthritis, Juvenile; Rheumatoid/complications; Child; Collagen/adverse effects;
Collagen/administration & dosage*; Drug Therapy, Combination; Female; Human; Male;
Pilot Projects; Severity of Illness Index; Support, Non-U.S. Gov't; Support, U.S. Gov't,
P.H.S.; Treatment Outcome
Substances:
Collagen
PMID: 8630112, MUID: 96226199